Advanced Magnetics ferumoxytol enters Phase III
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Advanced Magnetics anticipates submitting an NDA for its iron replacement therapy ferumoxytol for use in anemic chronic kidney disease (CKD), regardless of dialysis status, by the end of 2005. The firm has initiated two identical Phase III trials in anemic CKD patients not yet on dialysis; a Phase III study in anemic CKD patients on dialysis is slated to begin in the second-quarter. Advanced Magnetics anticipates the initiation of Phase III trials for use in magnetic resonance angiography before the end of 2004...
You may also be interested in...
Advanced Magnetics ferumoxytol update
Advanced Magnetics plans to submit an NDA for its iron replacement therapy ferumoxytol for use in anemic chronic kidney disease patients, regardless of dialysis status, "during the first half of 2006," the firm says Jan. 13. Submission was previously projected by the end of 2005 (1Pharmaceutical Approvals Monthly May 1, 2004, In Brief). The company also announced initiation of a large-scale, multi-center Phase III safety study, which will be the last study in the iron therapy program. Ferumoxytol is also in "exploratory Phase II clinical studies for use as a contrast agent in magnetic resonance angiography"...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.